| Bioactivity | (±)-Lisofylline ((±)-Lisophylline) is the racemate of Lisofylline. Lisofylline inhibits the generation of phosphatidic acid and free fatty acids. Lisofylline also blocks the release of pro-inflammatory cytokines in oxidative tissue injury, in response to cancer chemotherapy and in experimental sepsis. Lisofylline can be used for Type 1 diabetes research[1]. | ||||||||||||
| Name | (±)-Lisofylline | ||||||||||||
| CAS | 6493-06-7 | ||||||||||||
| Formula | C13H20N4O3 | ||||||||||||
| Molar Mass | 280.32 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Yang Z, et al. Lisofylline: a potential lead for the treatment of diabetes. Biochem Pharmacol. 2005 Jan 1;69(1):1-5. |
(±)-Lisofylline
CAS: 6493-06-7 F: C13H20N4O3 W: 280.32
(±)-Lisofylline ((±)-Lisophylline) is the racemate of Lisofylline. Lisofylline inhibits the generation of phosphatidic
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.